Sage Journals: Discover world-class research

Retricted access

Article commentary

First published 2019-1

Inferior outcomes in immunocompromised Merkel cell carcinoma patients: Can they be overcome by the use of PD1/PDL1 inhibitors?

Constantin A Dasanu, Michael Del Rosario, Ion Codreanu [...]

Journal of Oncology Pharmacy Practice

Open access

Research article

First published 2020-7

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?

Yulin Wan, Shanshan An, Yanchao Zhou [...]

Cancer Control

Retricted access

Case report

First published 2021-2

Phospholipase A2 receptor antibody mediated membranous nephropathy associated with cemiplimab

Marco Bonilla, Boonyanuth Maturostrakul, Neelofar Khan [...]

Journal of Onco-Nephrology

Open access

Research article

First published 2021

Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database

Abdulaali R. Almutairi, Marion Slack, Brian L. Erstad [...]

Therapeutic Advances in Drug Safety

Retricted access

Case report

First published 2024-12

Successful treatment of PD1-inhibitor induced psoriasiform dermatitis using IL-17 blockade without compromising immunotherapy efficacy

Adina Greene, Scott Penner, Amanda Edmond [...]

Journal of Oncology Pharmacy Practice

Open access

Review article

First published 2021

Immune checkpoint inhibitors in ovarian cancer: where do we stand?

Alexandra Leary, David Tan, Jonathan Ledermann

Therapeutic Advances in Medical Oncology

Retricted access

Case report

First published 2019-6

Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma

Yazeed Samara, Chun Lai Yu, Constantin A Dasanu

Journal of Oncology Pharmacy Practice

Open access

Case report

First published 2023

A multidisciplinary approach to treating a unique case of recurrent metastatic thymic carcinoma: case report

Carol Wang, David Erick Elkowitz, Michael John Esposito [...]

Therapeutic Advances in Rare Disease

Open access

Review article

First published 2023

What is the optimal duration,dose and frequency for anti-PD1 therapy of non-small cell lung cancer?

Chii Yang Kuah, Robert Monfries, Matteo Quartagno [...]

Therapeutic Advances in Medical Oncology

Open access

Case report

First published 2021

Dramatic response of refractory metastatic squamous cell carcinoma of the skin with cetuximab/pembrolizumab

Candice Hober, Philippe Jamme, Eve Desmedt [...]

Therapeutic Advances in Medical Oncology

Search results